Physician profile
Christopher M Conti
NPI 1801890397
$2,057.51
in general payments reported to CMS, 2019-2025
22 companies · $285 in 2025
The $285 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72.16 · 2022: $267 · 2023: $587 · 2024: $846 · 2025: $285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,718.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $341.46 | 2022-2025 | Simponi Aria, Simponi, Stelara |
| Kerecis Limited | $285.77 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Incyte Corporation | $249.41 | 2023-2025 | Opzelura |
| Dermavant Sciences, INC. | $206.26 | 2023-2024 | Vtama |
| Ucb, INC. | $197.29 | 2023-2025 | Bimzelx, Cimzia |
| Organogenesis INC. | $125.00 | 2022 | |
| Lilly USA, LLC | $103.20 | 2022 | |
| Amgen INC. | $94.42 | 2023-2024 | Otezla |
| Leo Pharma INC. | $87.10 | 2024-2025 | Adbry |
| Sun Pharmaceutical Industries INC. | $51.09 | 2023-2024 | Ilumya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.00 | 2023-2024 | Spevigo |
| Regeneron Healthcare Solutions, INC. | $47.99 | 2022-2024 | Dupixent |
| Organon LLC | $40.28 | 2025 | Vtama |
| Bard Peripheral Vascular, INC. | $26.72 | 2025 | Venclose Maven Catheter |
| Mallinckrodt Hospital Products INC. | $26.54 | 2024 | Acthar |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $20.59 | 2019 | |
| Galderma Laboratories, L.P. | $18.80 | 2025 | Aklief |
| Krystal Biotech INC | $18.77 | 2024 | Vyjuvek |
| Dusa Pharmaceuticals, INC. | $17.73 | 2019 | |
| Smith+Nephew, INC. | $17.51 | 2019 | |
| Biofrontera INC. | $16.33 | 2019 | |
| Strata Skin Sciences, INC. | $15.25 | 2025 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Conti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.